- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 513/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains two hetero rings
Patent holdings for IPC class C07D 513/02
Total number of patents in this class: 171
10-year publication summary
|
12
|
6
|
5
|
6
|
6
|
5
|
2
|
3
|
7
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3748 |
9 |
| Bristol-myers Squibb Company | 4898 |
8 |
| Biosplice Therapeutics, Inc. | 171 |
6 |
| Merck Patent GmbH | 5831 |
3 |
| Astex Therapeutics Limited | 237 |
3 |
| Crestone, Inc. | 15 |
3 |
| Daiichi Sankyo Company, Limited | 1869 |
3 |
| The Hong Kong University of Science and Technology | 750 |
3 |
| Janssen Sciences Ireland UC | 183 |
3 |
| Neurocrine Biosciences, Inc. | 419 |
3 |
| Eisai R&D Management Co., Ltd. | 1233 |
3 |
| L'OREAL, Société Anonyme | 15488 |
2 |
| Novartis AG | 10849 |
2 |
| Takeda Pharmaceutical Company Limited | 2713 |
2 |
| Vertex Pharmaceuticals Incorporated | 1597 |
2 |
| Askat Inc. | 52 |
2 |
| Cancer Research Technology Limited | 523 |
2 |
| Carna Biosciences, Inc. | 62 |
2 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 702 |
2 |
| The Global Alliance for TB Drug Development, Inc. | 43 |
2 |
| Other owners | 106 |